ID   OV-866(2)
AC   CVCL_9T22
SY   OV866(2); OV-866 (2)
DR   cancercelllines; CVCL_9T22
DR   CancerTools; 161767
DR   Wikidata; Q54936832
RX   PubMed=26622941;
CC   Doubling time: 1.77 +- 0.32 days (PubMed=26622941).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg249Trp (c.745A>T); ClinVar=VCV000141881; Zygosity=Unspecified (PubMed=26622941).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Variations; SNP array analysis.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson, Anne-Marie.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 10,11
ST   D21S11: 29,30.2
ST   D5S818: 13
ST   D7S820: 9,11
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 10-04-25; Version: 14
//
RX   PubMed=26622941; DOI=10.18632/genesandcancer.76; PMCID=PMC4633166;
RA   Fleury H., Communal L., Carmona E., Portelance L., Arcand S.L.,
RA   Rahimi K., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Novel high-grade serous epithelial ovarian cancer cell lines that
RT   reflect the molecular diversity of both the sporadic and hereditary
RT   disease.";
RL   Genes Cancer 6:378-398(2015).
//